Clinical Trial Update: Double Dose of Third-generation EGFR-TKI Plus Intrathecal Pemetrexed Versus Double Dose of Third-generation EGFR-TKI in Patients With LM Progression Following the Treatment of Routine Dose of Third-generation EGFR-TKI [Phase 2]

View source ↗

Summary

Phase 2 trial assessing double-dose third-generation EGFR-TKI with intrathecal pemetrexed versus double-dose third-generation EGFR-TKI in leptomeningeal metasta…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leptomeningeal Metastasis

Drugs mentioned

• Pemetrexed (intrathecal) (pemetrexed)
• Third-generation EGFR-TKI

Snippet

Sponsor: Fujian Cancer Hospital | Conditions: Leptomeningeal Metastasis | Phase 2 | Status: NOT_YET_RECRUITING